Enzymatica's sales and result affected by the pandemic

"We remain equally positive in the longer perspective, but the current situation with the pandemic will postpone Enzymatica's development for about 12 - 18 months. The new share issue will provide us with the resources needed for working capital for 2021, as well as ensuring the long-term investments in our continued rapid expansion," says Bengt Baron, Executive Chairman at Enzymatica. "We remain equally positive in the longer perspective, but the current situation with the pandemic will...

"We remain equally positive in the longer perspective, but the current situation with the pandemic will postpone Enzymatica's development for about 12 - 18 months. The new share issue will provide us with the resources needed for working capital for 2021, as well as ensuring the long-term investments in our continued rapid expansion," says Bengt Baron, Executive Chairman at Enzymatica.

Despite the decline of the common cold market, Enzymatica's sales is bolstered by the launch of ColdZyme in new markets, such as France and Italy, where the product has been received well by consumers. In 2020 Enzymatica entered into agreements with large international pharmaceutical and self-care companies for marketing and sales of ColdZyme in about 50 markets. Today ColdZyme is sold in about 30 of these markets. Launches for the remaining markets are mainly expected to occur during 2021-22, but the launch in some markets might be delayed due to the pandemic and approvals by regulatory authorities.

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 3 pm on 22 March, 2020.

For more information, please contact:

Bengt Baron, Executive Chairman, Enzymatica AB
Phone: +46 (0)708-59 30 09 | Email: [email protected]

Claus Egstrand, Chief Operating Officer & Senior Director Growth Enzymatica AB
Phone: +44 7780 22 8385 | E-mail: [email protected]

Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: +46 (0)701-88 50 21 | Email: [email protected]

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica's certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/enzymatica-s-sales-and-result-affected-by-the-pandemic,c3311757

The following files are available for download: